Compare SABR & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SABR | EMBC |
|---|---|---|
| Founded | 2006 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 580.9M | 521.7M |
| IPO Year | 2014 | 2021 |
| Metric | SABR | EMBC |
|---|---|---|
| Price | $1.50 | $9.03 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $2.50 | ★ $18.50 |
| AVG Volume (30 Days) | ★ 13.4M | 748.8K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 6.75% |
| EPS Growth | ★ 283.56 | 20.90 |
| EPS | ★ 1.34 | 0.74 |
| Revenue | ★ $3,866,956,000.00 | N/A |
| Revenue This Year | $7.40 | $1.17 |
| Revenue Next Year | $3.26 | N/A |
| P/E Ratio | ★ $0.98 | $12.04 |
| Revenue Growth | ★ 7.46 | N/A |
| 52 Week Low | $0.81 | $8.72 |
| 52 Week High | $3.51 | $15.55 |
| Indicator | SABR | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 52.88 | 39.08 |
| Support Level | $1.49 | N/A |
| Resistance Level | $1.70 | $10.88 |
| Average True Range (ATR) | 0.17 | 0.34 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 29.29 | 27.23 |
Sabre holds the number-two air booking volume share in the global distribution system industry. The distribution segment represented 80% of total 2025 revenue and airline IT solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.